Appreciability andDe Minimisin Article 102 TFEU
نویسندگان
چکیده
منابع مشابه
Current Intelligence General Court confirms the comprehensive effec- tiveness of the Commis- sion’s inspection powers vis-à-vis professional associations and their governing bodies
The prohibition under Article 101(1) TFEU puts restrictive decisions of associations of undertakings on an equal footing with restrictive agreements or concerted practices between undertakings. The main reason for this is that by coordinating the competitive behaviour of the members of the association in a restrictive way, such decisions may be just as detrimental for competition as restrictive...
متن کاملNpgrj_nchembio_760 95..102
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the molecular level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity. Encouraged by the clinical validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacological agents that could target this kinase by a distinct mech...
متن کاملTf-ilpr150008 96..102
Previous studies from this group have shown that limit size lipid-based systems – defined as the smallest achievable aggregates compatible with the packing properties of their molecular constituents – can be efficiently produced using rapid microfluidic mixing technique. In this work, it is shown that similar procedures can be employed for the production of homogeneously sized unilamellar vesic...
متن کاملPg 102-107
Great strides were made during the last century in the management of diabetes in pregnancy. Before the discovery of insulin in 1921 the outlook for the diabetic mother and her fetus was abysmal. With the advent of insulin, an emphasis on a team approach to care, improved methods of fetal surveillance, and a focus on metabolic normalisation brought about by intensive insulin regimens and home gl...
متن کاملDmd065615 102..114
N-Methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide (axitinib) is an oral inhibitor of vascular endothelial growth factor receptors 1–3, which is approved for the treatment of advanced renal cell cancer. Human [C]-labeled clinical studies indicate axitinib’s primary route of clearance is metabolism. The aims of the in vitro experiments presented herein were to identify an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of European Competition Law & Practice
سال: 2016
ISSN: 2041-7764,2041-7772
DOI: 10.1093/jeclap/lpw072